PTX 2.44% 4.2¢ prescient therapeutics limited

Ann: PTX-100 trial advances following successful Phase 1b, page-288

  1. 127 Posts.
    lightbulb Created with Sketch. 72
    Thanks, this made me go have a look at competitor pipelines. I was a bit sceptical about PTX 100 being a large driver of growth, but after looking at the broad scope that is being applied when just targeting KRASG12C + G12D, I reckon I was pretty wrong especially if it plays well with other therapies.

    Found this Miranti presentation interesting for context
    https://s27.q4cdn.com/140416303/files/doc_presentation/2021/09/Mirati_Corporate-Presentation_20September2021_FINAL_PDF.pptx.pdf



 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.